【线上讲座】 Dr. Guo from Ionis

InT@UCLA| 2023.02.05

时间：2月5日周日 4-5PM 美西时间，7-8PM 美东时间

Zoom 链接：

https://ucla.zoom.us/j/91963923742?pwd=S2tjck9GN1VFbWEyYy9IN21LWGFzQT09

注册及预约方式：

复制链接🔗

https://docs.google.com/forms/d/1530luXcM9c36t1zz5Uc0VUWe5G9aYV69HmzoMfKKITs/viewform?edit_requested=true

或长按下方二维码

Dr. Guo 嘉宾介绍

Shuling Guo, PhD

郭博士在杜克大学获得了分子癌症生物学博士学位，并在 HHMI/UCLA 接受了博士后培训。她于 2008 年加入 Ionis Pharmaceuticals，目前担任药物研发副总裁，并负责心肾、代谢和肺部的整体药物研发工作。她负责管理从靶点识别、靶点验证到选择人类发展候选药物的研究活动。此外，她还密切参与 RNA 疗法的临床开发。此外，郭博士一直在管理探索性研究活动，包括非编码 RNA、自噬/有丝分裂和无意义介导的 mRNA 衰变。迄今为止，郭博士已发表 70 多篇文章，其中大部分是关于反义技术在各个治疗领域的应用和机理。

Dr. Shuling Guo received her Ph.D. in Molecular Cancer Biology from Duke University and had her postdoctoral training at HHMI/UCLA. Since joining Ionis Pharmaceuticals in 2008, Dr. Guo has been taking on steadily increasing responsibilities, now serving as the Vice President of Drug Discovery. Dr. Guo oversees the overall drug discovery efforts in CardioRenal, Metabolic, and Pulmonary franchises. She manages research activities from target identification, target validation, to the selection of human development candidates. In addition, she is closely involved in the clinical development of RNA therapeutics. Furthermore, over the years, Dr. Guo has managed exploratory research activities including noncoding RNA, autophagy/mitophagy, and nonsense-mediated mRNA decay. To date, Dr. Shuling Guo has published over 70 articles, a majority of which are related to the applications and mechanisms of antisense technology in various therapeutic areas.

Ionis 公司介绍

Ionis Pharmaceuticals

Ionis Pharmaceuticals 是 RNA 治疗领域的领导者，致力于发现、开发和交付生命转化基因药物给有需要的患者。Ionis 的发现并开发 RNA 靶向药物的核心是反义技术，该技术可以降低致病蛋白质的水平，增加所需但缺乏的蛋白质的生产。Ionis 已批准的反义药物包括 Spinraza、Tegsedi 和 Waylivra，并有十余药物处于中后期开发阶段。

Ionis Pharmaceuticals is the leader in RNA therapeutics, dedicated to the discovery, development and delivery of life transforming genetic medicines to the patients in need. Its RNA targeted drug discovery and development revolve around Antisense technology, which can decrease the level of disease-causing proteins and increase the production of needed yet absent proteins. Ionis’ approved antisense-based medicines include Spinraza, Tegsedi, and Waylivra, with 10+ in mid- and late-state development.

官网链接🔗：